Citius Pharmaceuticals, Inc. (CTXR) Operating income 2016–2025
Citius Pharmaceuticals, Inc. (CTXR) annual operating income history from SEC filings — each fiscal year as reported.
-$38.5MFY2025 · since FY2016: -$7.4M → -$38.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$38.5M | +8.3% |
| FY2024 | -$42.0M | -14.3% |
| FY2023 | -$36.7M | -10.3% |
| FY2022 | -$33.3M | -41.6% |
| FY2021 | -$23.5M | -32.9% |
| FY2020 | -$17.7M | -13.5% |
| FY2019 | -$15.6M | -13.1% |
| FY2018 | -$13.8M | -38.1% |
| FY2017 | -$10.0M | -34.1% |
| FY2016 | -$7.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CTXR financial trends
CTXR RevenueCTXR Net incomeCTXR Net marginCTXR Gross profitCTXR Gross marginCTXR Operating marginCTXR Operating cash flowCTXR Free cash flowCTXR Capital expendituresCTXR Return on equityCTXR Stock buybacksCTXR Dividends paidCTXR Total assetsCTXR Total liabilitiesCTXR Shareholders’ equityCTXR overview →